Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease.

Sluiter RL, Van Marrewijk C, De Jong D, Scheffer H, Guchelaar HJ, Derijks L, Wong DR, Hooymans P, Vermeulen SH, Verbeek ALM, Franke B, Van der Wilt GJ, Kievit W, Coenen MJH.

J Crohns Colitis. 2019 Jul 25;13(7):838-845. doi: 10.1093/ecco-jcc/jjz009.

PMID:
30698675
4.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

5.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

6.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

7.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

8.

Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Kievit W, Klungel OH, Verbeek ALM, Wong DR, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Bouvy ML, de Jong DJ.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):167-173. doi: 10.1097/MEG.0000000000001025.

9.

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ.

Aliment Pharmacol Ther. 2017 Nov;46(10):953-963. doi: 10.1111/apt.14323. Epub 2017 Sep 15.

10.

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.

Broekman MMTJ, Coenen MJH, van Marrewijk CJ, Wanten GJA, Wong DR, Verbeek ALM, Klungel OH, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, de Jong DJ; TOPIC Recruitment Team.

Inflamm Bowel Dis. 2017 Oct;23(10):1873-1881. doi: 10.1097/MIB.0000000000001163.

11.

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.

Broekman MMTJ, Wong DR, Wanten GJA, Roelofs HM, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Coenen MJH, de Jong DJ.

Pharmacogenomics J. 2018 Jan;18(1):160-166. doi: 10.1038/tpj.2016.87. Epub 2017 Jan 3.

PMID:
28045129
12.

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.

Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC Recruitment Team.

Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12.

13.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.

14.

Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.

Wong DR, Coenen MJ, Vermeulen SH, Derijks LJ, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC recruitment team.

J Crohns Colitis. 2017 Feb;11(2):175-184. doi: 10.1093/ecco-jcc/jjw130. Epub 2016 Jul 9.

PMID:
27402913
15.

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team.

Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.

PMID:
26072396
16.

Patient adherence to prescribed medication instructions for dyspepsia: the DIAMOND-study.

Fransen GA, Mesters I, Muris JW, Van Marrewijk CJ, Mujakovic S, Laheij RJ, Numans ME, de Wit NJ, Samsom M, Jansen JB, Knottnerus JA.

Eur J Gen Pract. 2012 Jun;18(2):79-85. doi: 10.3109/13814788.2012.665443.

PMID:
22591059
17.

Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia.

Mujakovic S, ter Linde JJ, de Wit NJ, van Marrewijk CJ, Fransen GA, Onland-Moret NC, Laheij RJ, Muris JW, Grobbee DE, Samsom M, Jansen JB, Knottnerus A, Numans ME.

BMC Med Genet. 2011 Oct 20;12:140. doi: 10.1186/1471-2350-12-140.

18.

CT colonography with limited bowel preparation for the detection of colorectal neoplasia in an FOBT positive screening population.

Liedenbaum MH, de Vries AH, van Rijn AF, Dekker HM, Willemssen FE, van Leerdam ME, van Marrewijk CJ, Fockens P, Bipat S, Bossuyt PM, Dekker E, Stoker J.

Abdom Imaging. 2010 Dec;35(6):661-8. doi: 10.1007/s00261-009-9586-8.

19.

Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening.

Liedenbaum MH, van Rijn AF, de Vries AH, Dekker HM, Thomeer M, van Marrewijk CJ, Hol L, Dijkgraaf MG, Fockens P, Bossuyt PM, Dekker E, Stoker J.

Gut. 2009 Sep;58(9):1242-9. doi: 10.1136/gut.2009.176867. Epub 2009 Jul 21.

20.

Influence of gastric mucosal status on success of stepwise acid suppressive therapy for dyspepsia.

van Marrewijk CJ, van Oijen MG, Paloheimo LI, Fransen GA, Mujakovic S, Muris JW, Numans ME, De Wit NJ, Grobbee DE, Knottnerus JA, Laheij RJ, Jansen JB.

Aliment Pharmacol Ther. 2009 Jul;30(1):82-9. doi: 10.1111/j.1365-2036.2009.04001.x. Epub 2009 Mar 21.

21.

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus JA, Laheij RJ.

Lancet. 2009 Jan 17;373(9659):215-25. doi: 10.1016/S0140-6736(09)60070-2.

PMID:
19150702
22.

Psychopathology is associated with dyspeptic symptom severity in primary care patients with a new episode of dyspepsia.

Mujakovic S, de Wit NJ, van Marrewijk CJ, Fransen GA, Laheij RJ, Muris JW, Samsom M, Grobbee DE, Jansen JB, Knottnerus JA, Numans ME.

Aliment Pharmacol Ther. 2009 Mar 1;29(5):580-8. doi: 10.1111/j.1365-2036.2008.03909.x. Epub 2008 Dec 1.

23.

Procedure-related mortality of endovascular abdominal aortic aneurysm repair using revised reporting standards.

Koning GG, Vallabhneni SR, Van Marrewijk CJ, Leurs LJ, Laheij RJ, Buth J.

Rev Bras Cir Cardiovasc. 2007 Jan-Mar;22(1):7-13; discussion 13-4. English, Portuguese.

PMID:
17992299
24.

Pragmatic trials in primary care. Methodological challenges and solutions demonstrated by the DIAMOND-study.

Fransen GA, van Marrewijk CJ, Mujakovic S, Muris JW, Laheij RJ, Numans ME, de Wit NJ, Samsom M, Jansen JB, Knottnerus JA.

BMC Med Res Methodol. 2007 Apr 23;7:16. Review.

25.

Close contacts with leprosy in newly diagnosed leprosy patients in a high and low endemic area: comparison between Bangladesh and Thailand.

Richardus JH, Meima A, van Marrewijk CJ, Croft RP, Smith TC.

Int J Lepr Other Mycobact Dis. 2005 Dec;73(4):249-57.

PMID:
16830634
26.

Risk-adjusted outcome analysis of endovascular abdominal aortic aneurysm repair in a large population: how do stent-grafts compare?

van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, Harris PL, Buth J, Laheij RJ; EUROSTAR collaborators.

J Endovasc Ther. 2005 Aug;12(4):417-29.

PMID:
16048373
27.

Adjuvant procedures performed during endovascular repair of abdominal aortic aneurysm. does it influence outcome?

Hobo R, Van Marrewijk CJ, Leurs LJ, Laheij RJ, Buth J; Eurostar Collaborators.

Eur J Vasc Endovasc Surg. 2005 Jul;30(1):20-8.

28.

Impact of smoking on endovascular abdominal aortic aneurysm surgery outcome.

Lottman PE, Van Marrewijk CJ, Fransen GA, Laheij RJ, Buth J.

Eur J Vasc Endovasc Surg. 2004 May;27(5):512-8.

29.

Diameter of abdominal aortic aneurysm and outcome of endovascular aneurysm repair: does size matter? A report from EUROSTAR.

Peppelenbosch N, Buth J, Harris PL, van Marrewijk C, Fransen G; EUROSTAR Collaborators.

J Vasc Surg. 2004 Feb;39(2):288-97.

30.

Is a type II endoleak after EVAR a harbinger of risk? Causes and outcome of open conversion and aneurysm rupture during follow-up.

van Marrewijk CJ, Fransen G, Laheij RJ, Harris PL, Buth J; EUROSTAR Collaborators.

Eur J Vasc Endovasc Surg. 2004 Feb;27(2):128-37.

31.

Endoleaks during follow-up after endovascular repair of abdominal aortic aneurysm. Are they all dangerous?

Buth J, Harris PL, Van Marrewijk C, Fransen G.

J Cardiovasc Surg (Torino). 2003 Aug;44(4):559-66. Review.

PMID:
14627230
32.

Rupture of infra-renal aortic aneurysm after endovascular repair: a series from EUROSTAR registry.

Fransen GA, Vallabhaneni SR Sr, van Marrewijk CJ, Laheij RJ, Harris PL, Buth J; EUROSTAR.

Eur J Vasc Endovasc Surg. 2003 Nov;26(5):487-93.

33.

Emergency treatment of acute symptomatic or ruptured abdominal aortic aneurysm. Outcome of a prospective intent-to-treat by EVAR protocol.

Peppelenbosch N, Yilmaz N, van Marrewijk C, Buth J, Cuypers P, Duijm L, Tielbeek A.

Eur J Vasc Endovasc Surg. 2003 Sep;26(3):303-10.

34.

The significance and management of different types of endoleaks.

Buth J, Harris PL, van Marrewijk C, Fransen G.

Semin Vasc Surg. 2003 Jun;16(2):95-102. Review.

PMID:
12920679
35.

Factors and forces influencing stent-graft migration after endovascular aortic aneurysm repair.

Mohan IV, Harris PL, Van Marrewijk CJ, Laheij RJ, How TV.

J Endovasc Ther. 2002 Dec;9(6):748-55.

PMID:
12546574
36.

Life expectancy after endovascular versus open abdominal aortic aneurysm repair: results of a decision analysis model on the basis of data from EUROSTAR.

Schermerhorn ML, Finlayson SR, Fillinger MF, Buth J, van Marrewijk C, Cronenwett JL.

J Vasc Surg. 2002 Dec;36(6):1112-20.

37.

The influence of team experience on outcomes of endovascular stenting of abdominal aortic aneurysms.

Laheij RJ, van Marrewijk CJ, Buth J, Harris PL; EUROSTAR Collaborators.

Eur J Vasc Endovasc Surg. 2002 Aug;24(2):128-33.

38.

[Endovascular therapy of aneurysms of the abdominal aorta: report of 4,291 patients of the Eurostar Register].

Enzler MA, van Marrewijk CJ, Buth J, Harris PL.

Vasa. 2002 Aug;31(3):167-72. German.

PMID:
12236020
39.

Significance of endoleaks after endovascular repair of abdominal aortic aneurysms: The EUROSTAR experience.

van Marrewijk C, Buth J, Harris PL, Norgren L, Nevelsteen A, Wyatt MG.

J Vasc Surg. 2002 Mar;35(3):461-73.

40.

Outcome of endovascular abdominal aortic aneurysm repair in patients with conditions considered unfit for an open procedure: a report on the EUROSTAR experience.

Buth J, van Marrewijk CJ, Harris PL, Hop WC, Riambau V, Laheij RJ; EUROSTAR Collaborators.

J Vasc Surg. 2002 Feb;35(2):211-21.

41.

Causes and outcomes of open conversion and aneurysm rupture after endovascular abdominal aortic aneurysm repair: can type II endoleaks be dangerous?

Buth J, Harris PL, van Marrewijk C.

J Am Coll Surg. 2002 Jan;194(1 Suppl):S98-102. Review. No abstract available.

PMID:
11800362
42.

The evolving technique of endovascular stenting of abdominal aortic aneurysm; time for reappraisal.

Laheij RJ, van Marrewijk CJ; EUROSTAR Group.

Eur J Vasc Endovasc Surg. 2001 Nov;22(5):436-42.

43.

Spinal cord ischaemia after stent-graft treatment for infra-renal abdominal aortic aneurysms. Analysis of the Eurostar database.

Berg P, Kaufmann D, van Marrewijk CJ, Buth J.

Eur J Vasc Endovasc Surg. 2001 Oct;22(4):342-7.

44.

Three year single centre experience with the AneuRx aortic stent graft.

Tutein Nolthenius RP, van Herwaarden JA, van den Berg JC, van Marrewijk C, Teijink JA, Moll FL.

Eur J Vasc Endovasc Surg. 2001 Sep;22(3):257-64.

47.

On opulence driven poverty traps.

Van Marrewijk C, Verbeek J.

J Popul Econ. 1993;6(1):67-81.

PMID:
12285976
48.

Thioether excretion in urine of applicators exposed to 1,3-dichloropropene: a comparison with urinary mercapturic acid excretion.

van Welie RT, van Marrewijk CM, de Wolff FA, Vermeulen NP.

Br J Ind Med. 1991 Jul;48(7):492-8.

Supplemental Content

Loading ...
Support Center